Liver Cancer Cell Lines
Database

LCCL to predict drug response

Drug: Bortezomib

DrugsAliasTargetsTargeted cellular functionClinical status in any tumor typeClinical status in HCCSupplierReference
Bortezomib Velcade Proteasome Protein degradation Approved Phase 2 Selleck Chemicals S1013

Cell Line (34)
Cell LineAUCGI50
Mahlavu0.140.003
B10.160.003
HCC.1.10.220.007
JHH10.220.006
HLE0.240.006
HepaRG0.250.005
SNU7390.260.008
HCC.30.270.009
SNU3540.270.01
HLF0.30.013
Hep3B0.310.013
HCC.1.20.330.02
JHH50.350.015
SNU4490.370.02
SNU3870.370.024


LCCL transcriptomic subgroup:
CL1
CL2
CL3
undef.

Codebase Soc. Coop.
info@codebase.it